Drug intelligence / Profile preview

NB-303

Development stage: Preclinical
Lead developer: NeoLogics Bioscience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NB-303 is a monoclonal antibody drug candidate developed by Neologics Bioscience. It is being investigated for the treatment of neoplasms, specifically solid tumors. As of May 2025, its highest global R&D status is preclinical, and there are no reported clinical trial phases or approvals. The specific molecular target and mechanism of action have not been disclosed in public sources[2].

Beyond the preview

Go deeper on NB-303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NB-303.

Explore the full profile